BMJ Open Protocol for a prospective descriptive prevalence study of catatonia in an acute mental health unit in urban South Africa

Zukiswa Zingela,1 Louise Stroud,2 Johan Cronje,2 Max Fink,3 Stephanus van Wyk1


Pre-publication history and additional material for this paper is available online. To view these files, please visit the journal online (http://dx.doi.org/10.1136/bmjopen-2020-040176).

Received 26 May 2020
Revised 25 September 2020
Accepted 15 October 2020

ABSTRACT

Introduction Catatonia arises from serious mental, medical, neurological or toxic conditions. The prevalence range depends on the setting and the range is anything from 7% to 63% in other countries. South African prevalence rates are currently unknown. The proposed study is a quantitative descriptive study using the Bush Francis Catatonia Screening Instrument as a screening tool with a data capturing information sheet to extract clinical information from patient folders. The study will investigate: (1) prevalence of catatonia, (2) clinical and demographic correlates associated with catatonia, (3) predictors of catatonia, (4) response to treatment and (5) subjective experience of catatonia.

Methods and analysis The setting is an acute mental health unit (MUH) within a regional, general medical hospital in Nelson Mandela Bay, South Africa, which accepts referrals from within the hospital and from outlying clinics. Participants will be recruited from inpatients in the MUH from beginning of September 2020 to end of August 2021. Most admissions are involuntarily, under the Mental Health Care Act of 2002 with an age range of 13 to over 65 years. Participants who screen positive for catatonia will be followed up after discharge for 3 months to measure outcomes. Primary outcomes will include the 12-month prevalence rate of catatonia, descriptive and other data on presentation and assessment of catatonia in the MUH. Secondary outcomes will include data on treatment response, participants’ report of their subjective experience of catatonia and predictors of catatonia. Descriptive statistics, multivariate binomial logistic regression and univariate analyses will be conducted to evaluate associations between catatonia and clinical or demographic data which could be predictors of catatonia. Survival analysis will be used to examine the time to recovery after diagnosis and initiation of treatment. The 95% CI will be used to demonstrate the precision of estimates. The level of significance will be p≤0.05.

Ethics and dissemination The study has received ethical approval from the Research and Ethics Committees of the Eastern Cape Department of Health, Walter Sisulu University and Nelson Mandela University. The results will be disseminated as follows: at various presentations and feedback sessions; as part of a PhD thesis in Psychology at Nelson Mandela University; and in a manuscript that will be submitted to a peer-reviewed journal.

Strengths and limitations of this study

- This is the first study to examine the prevalence of catatonia in South Africa and aims to address the lack of data on prevalence rates of catatonia, presentation, optimal management, predictors and outcomes in this setting.
- The triangulation of information sources like the Bush Francis Catatonia Rating Scale, a validated catatonia screening tool, clinical notes, and subjective reports of catatonic episodes from the participants present a unique opportunity to investigate different aspects of catatonia.
- The descriptive nature of the study and the limited number of participants could limit the applicability of significant associations between variables regarding cause and effect and the generalisability of findings. The heterogenous nature of catatonia and inter-rater reliability of catatonia screening instruments are another source of potential limitations of the study.

INTRODUCTION

In the 1880s, Kraepelin described the prevalence of catatonia as close to 20% in 500 cases. Modern-day studies show a range from less than 10% to 63%.1–3 Catatonia is often treated by psychiatrists, even though underlying causes may be other medical conditions such as neurological, infectious, endocrine and substance-induced disorders.1 Grover et al4 described close to 40% of 205 patients who had delirium and two or more catatonic symptoms on the Bush Francis Catatonia Rating Scale (BFCRS).

Luchini et al6 characterised catatonia as an autonomous syndrome, frequently associated with mood disorders but also observed in patients with other conditions including neurological, neurodevelopmental, physical and toxic conditions. Current evidence has provided some answers about the categorisation of catatonia, clinical presentations, interventions and response to treatment.6–8
The current study will investigate the prevalence of catatonia in patients of the Dora Nginaza Hospital (DNH) mental health unit (MHU), associated risk factors and response to treatment. Due to the prominent role played by electroconvulsive therapy (ECT) in the treatment of catatonia, the results from this study may have applicability in public mental health planning, and availability of ECT in public hospitals.1

Catatonia in South Africa
There are currently no studies describing the prevalence of catatonia in South Africa (SA), which leaves clinicians blind to the burden of the disease linked to this potentially fatal syndrome. Clinicians may, therefore, be unaware of the importance of the assessment and detection of catatonia, leading to missed opportunities to intervene in what is a highly treatable condition.

White and Robins9 described 17 patients with catatonia in SA who received antipsychotic medication. There was a deterioration in their clinical presentation into neuroleptic malignant syndrome (NMS). The risk of precipitating NMS in this case series was linked to the administration of antipsychotics. This study also challenged the notion of NMS being viewed as a separate condition to catatonia. Since then, catatonia has not been widely studied in SA, despite the researchers’ observation that it continues to present a significant and sometimes life-threatening challenge. Another study conducted in SA described the treatment of 42 patients with catatonia with ECT.10 The current study represents the first stages of aiming to fill the gap in the existing research with a prospective study on prevalence and predictive data.

Prevalence of catatonia in other parts of the world
Fink and Taylor1 described a rate of catatonia of 10% in acutely ill psychiatric patients and Stuivenga and Morrens2 a rate of 16.9% when applying the Diagnostic Statistical Manual - 5 (DSM-5) criteria. Conditions found in association with a catatonic presentation have included psychiatric diagnoses like bipolar disorder, delirious mania, psychotic depression, schizophrenia and other medical conditions.2 6 In some instances, the cause leading to catatonia has been less well defined. DSM-5 has captured the multiple possible associations that occur with catatonia by including it as a specifier for mood disorders and schizophrenia or as linked to another medical condition.11 Catatonia also appears as an entity with undefined aetiology under ‘catatonia not otherwise specified’.8

Choice of screening tool and rating scale
In 1996, Bush et al designed the Bush Francis Catatonia Screening Instrument (BFCSI) a 14-item scale for screening for catatonia and a 23-item scale for rating severity of catatonia.12 They demonstrated that the scales were reliable and valid tools for diagnosis and evaluation of response to treatment. The scales have a dual utility of screening and measurement of the severity of catatonia. A systematic review of seven catatonia rating scales reported a similar finding when comparing the BFCSI with other tools to screen for catatonia.13 They recommend the BFCSI for routine use because of ease of use, reliability and validity. Wilson et al14 found 300 out of 339 patients with acute medical and psychiatric illness screened positive for catatonia when applying the BFCSI.

The BFCSI and BFCRS have been used successfully in the MHU as screening and rating scales for the past 9 years in the MHU which is the site of the current study. Other reasons supporting the utility of the scales in this study are: (1) the reported ease of use, (2) reliability, (3) validity as both a screening tool and a measure of severity and (4) its use since 2011 in the study site has not yielded any issues with applicability or appropriateness when used in this clinical setting. Figure 1 reflects the assessment tools and process that will be applied to assess participant and collect data.

Management of catatonia
The biological treatment for catatonia has advanced over the last century, from insulin coma therapy of the early 1930s and Meduna’s use of seizure-inducing camphor oil injections to Cerletti’s first documented use of an electric shock procedure in 1938.1 Available evidence on management of catatonia includes the published works from various researchers.1 6 7 9 14–19 Lorazepam and ECT are the current recommended treatments, irrespective of aetiology. They are effective in most cases.17 19 14 17

In both the White and Robins9 and Fricchione et al7 case series, intravenous administration of benzodiazepines (diazepam or lorazepam) was demonstrated as an efficacious treatment for catatonia. Response is seen relatively rapidly, that is, within minutes of administration. Instead of a sedative effect that one observes with...
the administration of benzodiazepines in non-catatonic patients, those with catatonia tend to ‘wake up’ from stupor or normalise from a state of extreme excitement. In the White and Robins study, two patients who did not receive intravenous benzodiazepines died.

The dose range used at the study site tends to be higher and is given more frequently compared with the recommendation in the Rasmussen et al paper. This is mainly because patients at the site present at advanced stages of catatonia and tend to respond slowly or not at all when the lower or less frequent doses are employed.

The subjective experience of catatonia

Northoff et al conducted a retrospective study on 24 catatonic patients post recovery after a catatonic episode. The patients reported intense emotions which could not be controlled and ambivalence with less focus on their altered movements. Other descriptions of catatonia have stated an extreme fear response characterised by freezing, likened to the defence seen in animals of tonic immobility or freezing in the face of danger.

This study will investigate the subjective experience of catatonia as described by participants once discharged from the hospital, to shed light on the emotive and cognitive experience of catatonia in the study cohort. This may provide clues on the psychological drivers of the catatonic response and could pave the way for further research into the psychology of the catatonic response.

Aims

This study aims to determine the prevalence of catatonia in an acute MHU in urban SA and research its assessment and management in this setting.

Objectives

The two main research objectives are:

1. Screening of consenting participants admitted to the MHU in DNH using the BFCSI for catatonia, over a 12-month period from the 1 September 2020 to the end of August 2021, to describe the prevalence of catatonia in this setting.
2. Description of demographic and clinical information, including response to treatment, in participants diagnosed with catatonia based on their BFCSI scores and clinical assessments performed by the admitting doctor.

Response to treatment will be according to the following parameters: a 50% reduction in signs and symptoms will be considered a response while a 100% reduction will be a considered a full resolution. Conversely, a reduction in symptoms of less than 50% will be regarded as a suboptimal response and a reduction that is more than 50% but less than 100% will be a response but without full resolution. In addition, significant clinical correlates and risk factors in participants with catatonia will be described, and participants with catatonia will be followed up once discharged at 1-month, 2-month and 3-month intervals, to assess outcomes using the BFCSI and information about readmission or recurrence of any episode of mental illness. The association that will be looked at is between catatonia and demographic or clinical correlates such as age, gender, DSM-5 diagnosis, substance use, vitamin 12 deficiency and food insecurity and other co-occurring medical conditions. Participants’ experience of catatonia once it has resolved will also be described.

Research design

This is a prospective, descriptive triangulation study using mixed quantitative and qualitative methods. An exploratory qualitative aspect will investigate the emotive and cognitive subjective experience of participants with catatonia to establish a direction for further research. This is because there are currently limited data available on the subjective experience of catatonia, with most research focusing on quantitative aspects.

The quantitative elements of the study will include data collected from participant files of BFCSI scores on admission, with additional clinical and demographic information collected via a predesigned datasheet (see online supplemental appendix 1). The qualitative element will describe the participant’s reported experience of the catatonic episode, post discharge.

METHODS AND ANALYSIS

The study will take a positivist paradigm approach to investigate the potential causal relationships between catatonia and different variables via correlational studies. Creswell described the positivist’s approach as an attempt to identify causes, which influence outcomes, the aim being to formulate laws, thus yielding a basis for prediction and generalisation. In the current study, deductive reasoning will be applied to data collected through (1) direct observation and (2) quantitative and qualitative approaches, to identify associations with catatonia, causal relationships, and possibly, predictors of catatonia.

Sources of information that will be used for triangulation include: the participants’ BFCSI/ BFCRS scores (see online supplemental appendix 2) and clinical notes; field notes taken by the research team during direct observation and interviews; and participant and relative interviews focusing on response to treatment, food insecurity and the subjective experience of catatonia. Additionally, the mixed methods nature of the study will enable the generation of both objective (as documented by treating and research teams) and subjective data regarding the experience of catatonia. This type of triangulation is an important tool for meeting the goals of this study while facilitating a holistic assessment of catatonia in this cohort.

The study process and outline

Two research assistants (RAs) with a background in health will be recruited to assist the researcher with fieldwork. A health background is necessary to understand the medical terminology that is used in the clinical notes and
The study process. BFCSR, Bush Francis Catatonia Rating Scale; UBACC, University of California, San Diego Brief Assessment of Capacity to Consent Questionnaire.

screening tools. A part-time administrative assistant will be contracted to assist with data capturing and collation. Fieldwork will include the recruitment of participants and collection of data by the researcher and RAs. There will be a limited follow-up component that extends to up to 3 months following discharge from the hospital. The RAs will be trained by the researcher on:

1. Application of the BFCSI and BFCSR to ensure they are knowledgeable about the screening tool and its interpretation.
2. Assessment of capacity to consent using the University of California, San Diego Brief Assessment of Capacity to Consent Questionnaire (UBACC).

The UBACC has been applied successfully in the Eastern and Western Cape in study cohorts recruited from inpatient mental health institutions.24 25

The inter-rater reliability (IRR) of the BFCSR was demonstrated to be good (α=0.779) in a study looking at four different instruments to assess for catatonia.26 In the planned study, training that will be provided by the lead researcher to the RAs on the use of the BFCSI/BFCSR will be through:

- Explaining the meaning of terms used in the BFCSI/BFCSR to describe clinical signs and symptoms of catatonia.
- Providing a demonstration of how to elicit and document the 14-items and 23-items in the BFCSI/BFCSR, and how to capture the relevant information accurately onto the data capturing form.
- Ensuring RAs start with practice participants initially under direct observation of the lead researcher, before starting the actual recruitment. An IRR in the range of (α=0.61–0.8) during the practice scoring will be deemed acceptable for RAs to proceed to the scoring of study participants.

IRR will also be addressed through ensuring that everyone has a similar understanding of all items to be rated in the screening tool and how these should be recorded.

The researcher and RAs will assess participants who meet the inclusion criteria for capacity to consent, using the UBACC. All those with intact capacity to consent will be requested to consider entering the study (see online supplemental appendices 3 and 4). For participants who may be assessed as lacking the capacity to consent, their closest relatives or guardians will be requested to consent on their behalf through proxy consent (proxy consent and its ethical application are further discussed in the section ‘Ethics and dissemination’). Additionally, in those assessed to lack capacity to consent, such capacity will be reviewed weekly to allow for further re-engagement on their consent to take part in the study, the ultimate aim being to change from proxy consent to personal consent as soon as potential participants have regained capacity.

Data collected about any participant who chooses to withdraw from the study will be removed from the study data sets and destroyed.

The research team will collect data from the clinical files of consenting participants on BFCSI/BFCSR scores and additional descriptive and demographic information as guided by the study questionnaire and study protocol. The completed data capturing forms will be submitted to the administrative assistant for data collation and entry into a spreadsheet at the end of each week. The assessment of new admissions will be daily on weekdays with the expectation being to conduct daily screening or within the first 48 hours at least. Information on clinical presentation of patients admitted over weekends will be supplemented from the clinical folders. In cases where the researcher or RAs identify possible missed catatonia, the treating doctor will be provided with any additional information picked up during the participants’ assessment to allow for a review of the patient’s clinical case and management.

During the limited follow-up period, the researcher and RAs will repeat the BFCSI assessment and conduct face-to-face interviews with participants regarding their experience of catatonia at 1 month, 2 months and 3 months post discharge. Recurrence of symptoms or readmissions since the last discharge will be documented. The participant’s willingness to continue with the study will be reviewed during every visit to ensure their consent remains valid throughout. Figure 2 shows a summary of the study process that will be followed.

**Setting**

The setting will be a 35-bed acute MHU in DNH, a general hospital in the Eastern Cape Province in SA. The hospital is in Zwide, in the iBhayi area of Port Elizabeth which has a population of over one million within an urban area that has a high morbidity of mental illness.27 Close to 70% of the population comprises working age adults between 15 and 64 years and the city has an unemployment rate of close to 30%.27 Zwide itself has a population of 238 000.28 Health services in the hospital include obstetrics and gynaecology, paediatrics, basic surgical, internal medicine and family medicine. The MHU is an acute inpatient unit offering 24 hours care to persons who present with acute mental illness requiring inpatient treatment. It accepts referrals from all the other hospital departments.
including the accident and emergency department, as well as referrals from primary care clinics and district hospitals in the nearby vicinity. The usual period of admission ranges anything from 3 days to a few weeks.

All cases of suspected catatonia, from any of the referring departments, are discussed with the MHU team and prioritised for admission into the unit. Any treatment given thereafter is discussed with the MHU team and documented in the patient’s folder.

**Sampling**

Convenience sampling of all patients admitted to the MHU over a 12-month period (September 2020 to August 2021) will be undertaken. Contact details of all consenting participants who screen positive for catatonia will be entered into a database to enable contact for future follow-up at the end of 1 month, 2 months and 3 months post discharge. This information will be password encrypted.

The number of patients expected to be admitted during the study period is around 1000 based on previous unit stats over the last 3years and adjusted down slightly to accommodate the effect of the COVID-19 outbreak on hospital admissions. The margin of error or CI will be set at 95% and the SD will be set at 0.05. To determine the total sample size required, the formula: n=N/(1+Ne²) will be used and yields a minimum sample size of 286 subjects. A further 20% (57) will be added to account for data entry errors and non-responses. The appropriate sample size of participants to be screened for the prevalence of catatonia in the unit is 345.

**Participants**

Most people admitted to the DNH MHU are involuntary admissions under the Mental Health Care Act of 2002. Age of admission ranges from 13 to over 65 years because there are no child, adolescent or geriatric inpatient-specific services in the region.

**Inclusion criteria**

All patients admitted to the unit during the study period will be eligible for inclusion.

Those who screen positive for two or more catatonic signs and symptoms on the BFCSI will be included during the follow-up period for the qualitative part of the study.

**Exclusion criteria**

Refusal to take part in the study, whether through the direct patient consent process or the proxy consent process, will result in the exclusion of the patient.

**Methods of assessment and measurement**

The BFCSI is a 14-item scale (see online supplemental appendix 2) that is used to screen for catatonia and the BFCRS is a 21-item scale used to rate severity. The BFCSI is used on initial assessment and the full BFCRS is used to determine severity. Participants’ responses to the standard interventions of intravenous lorazepam administration or ECT will be documented by the admitting doctor in the case notes. The research team will then capture this information on a predesigned data collection sheet. When a patient presents with two or more positive items on the BFCSI, they are deemed catatonic and further management is guided by the unit protocol. A lorazepam infusion of 1 mg or 2 mg is administered and a response of 50% or greater reduction in the scale score verifies the diagnosis although absence of verification does not exclude catatonia. The research team will capture information on participant’s BFCSI/BFCRS scores and other clinical data on a predesigned data collection sheet.

The clinical data that will be collected include current psychiatric diagnosis, co-occurring medical conditions, any other treatment administered, history of substance use, history of previous catatonic episodes, vital signs like temperature on admission, blood pressure, pulse, investigations like creatine kinase, iron levels, thyroid function tests, urea and electrolytes or any other relevant clinical investigations reflected in the file which are noted by the treating team to be of relevance to the current admission, and food insecurity. The participants’ case notes will form a primary source of information as well as direct observation of the participants. Additional information will be sought from relatives if the participant is unable to respond adequately to information required on food security questions due to the severity of catatonic symptoms, or in those who are unable to provide the additional information for whatever other reason.

Regarding social determinants of mental health, current evidence indicates that those who are poor or disadvantaged suffer disproportionately from common mental disorders and their adverse consequences. The strength of the association with poverty has at times varied depending on the type of poverty measure used. Food insecurity as a poverty measure is one of the factors with a consistent and strong association with common mental disorders. In this study, the administration of a food security questionnaire will be used to assess the correlation of poverty to catatonia. Two food insecurity questions are drawn from the United Stated Department of Agriculture’s 18-question Household Food Security Scale. They make up The Hunger Vital Sign Questionnaire, a validated two-question food insecurity screening tool used in the clinical setting. The questions are:

1. Within the past 12 months, we worried whether our food would run out before we got money to buy more.
2. Within the past 12 months, the food we bought just did not last and we did not have money to get more.

During the follow-up period, participants will be asked to describe their experience of the catatonic episode as well as their perception of recovery.

**Expected outputs**

- The 12-month prevalence rate of catatonia.
- Descriptive and other data on presentation and assessment of catatonia in the DNH unit.
- Data on treatment response, short-term outcomes and subjective experience of catatonia.
Predictors for catatonia based on clinical correlates and other descriptive data collected.

Recommendations and guidelines for the management of catatonia and possible prevention strategies.

Data management and analysis
Quantitative data collected will be summarised using descriptive statistics. Categorical variables will be presented using frequency tables, percentages and graphs. Two or more categorical variables will be compared using contingency tables (eg, 2×2 table) and the expected frequencies will be calculated to determine the type of test best suited to determine the extent of any identified relative associations. If the expected frequencies in all cells are ≥5, then the $\chi^2$ test will be used and if the expected frequencies are <5 in any cells, then the Fisher’s exact test will be used.

Binomial logistic regression will also be conducted to determine the predictors of catatonia and to estimate the risk ratio. If the numerical data are not normally distributed, non-parametric statistics will be used (median and IQR). The best fitting model of multivariate analysis will be chosen through forward selection of model building. The model with the lowest Bayesian information criterion will be selected as the better model and the 95% CI will be used to estimate the precision of estimates. Survival analysis will be used to determine the time to recovery and the HR (ie, the total number and timing of each event indicating relapse in this study) will be reported for this purpose.

Qualitative data collated during the follow-up period will be analysed to elucidate the subjective experience of catatonia in this cohort. Aspects of the thematic analysis presented by Braun and Clarke will be applied to identify themes. Themes will be identified through a framework approach identifying word repetition, local expressions, metaphors and similarities, differences and keywords. A tentative hypothesis and theory regarding the experience of catatonia will be presented based on emergent themes. Data collected during the quantitative and qualitative segments of the study will be analysed separately but compared for congruency of reported information to enhance data integration.

In summary, data integration will be in the form of:
1. Converting information gathered from the quantitative aspects of the study into numerical information that can be processed through application of statistical methods to test for correlations and associations.
2. Identifying common themes through field notes taken when interviewing participants during the outpatient stage of the study.
3. Assessing congruency between common themes about the subjective experience of catatonia as described by participants and commonly identified presenting symptoms as highlighted in case notes and listed in the data collection sheet. The advantage of this approach is that it strengthens the validity and reliability of the study.

Patient and public involvement
No formal patient advisory committee was set up and there was no patient or public involvement in the design and planning of the study.

Ethics and dissemination
Ethics clearance has been granted for the study by the Eastern Cape Department of Health Ethics Committee (see online supplemental appendix 5 and 6), the Walter Sisulu University Research and Ethics Committee and the Nelson Mandela University Human Research Ethics Committee (see online supplemental appendix 7). The study does not have any intervention arm.

All patients admitted to the unit will be presented with an information leaflet on the study in English or Xhosa. Consent for inclusion in the study will be obtained from all participants who have the capacity to consent, which will be determined through application of the UBACC. Proxy consent will be sought from a relative or guardian for all patients who lack the capacity to consent or are minors between the ages of 13 and 18 years of age. The use of proxy consent in mental health research is applicable for those who lack the capacity to consent and the nearest relative or guardian consents on their behalf. It is permissible within the mental healthcare setting due to the challenges with capacity to consent that may exist in patients with acute mental illness. Proxy consent ensures that respondents’ rights are guarded while making it possible to include individuals or groups who may potentially benefit from scientific advances gained from research. This approach is also supported by the Helsinki Declaration on ethical research which states that ‘for a research subject who is legally incompetent, physically or mentally incapable of giving consent or is a legally incompetent minor, the investigator must obtain informed consent from the legally authorised representative in accordance with applicable law’. The Department of Health Guidelines on ethics in health research similarly state that persons should not be excluded unfairly based on discrimination or disability. The Mental Healthcare Act (MHCA) of 2002 also makes a reference as to whom may be considered an associate of a patient admitted under the MHCA: for example, a spouse, next of kin, partner, associate, parent or guardian.

A similar approach will be taken for this research. All data will be anonymised and stored under lock and key, with access granted to the research team only.

Dissemination of results
The results will be presented at feedback sessions with the Hospital Board, Eastern Cape Department of Health and at national and international congresses and may be used to compile guidelines on assessment and management of catatonia in the region. They will also be compiled as a thesis, which will be submitted for examination for a PhD in Psychology at Nelson Mandela University. A research report based on the study results will be submitted to peer-reviewed journals to be considered for publication.
Acknowledgements The authors thank Sikhumbuzo Mabunda for the valuable comments and assistance provided in the data analysis section.

Contributors ZZ conceived the idea and devised the project and its main conceptual ideas assisted by SwW and MF. LS and JC supervised the development of this manuscript and provided editorial input.

Funding This work was supported by the South African Medical Research Council (SAMRC), grant tracking number 2017SAMRCSR0000157977 and an educational grant from the Health and Welfare Sector Education and Training Authority (2018/2019HWSETA219866789).

Competing interests None declared.

Patient consent for publication Not required.

Provenance and peer review Not commissioned; externally peer reviewed.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any errors and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iD
Zukiswa Zingela http://orcid.org/0000-0002-3425-1145

REFERENCES


22 Scotland J. Exploring the philosophical underpinnings of research: relating ontology and epistemology to the methodology and methods of the scientific, interpretive, and critical research paradigms. English Language Teaching 2012;5:9–16.


## APPENDICES
### APPENDIX 1: DATA COLLECTION SHEET

<table>
<thead>
<tr>
<th>Enrolment No:</th>
<th>Tick applicable box or insert answer in area shaded in white</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Unit</strong></td>
<td>Is the Patient Catatonic now? (Fill in the BFCRS item 1 to 14 to answer this question), 2 or more signs mean Yes, there is catatonia</td>
</tr>
<tr>
<td><strong>DNH</strong></td>
<td>If No then tick this box and fill in ONLY Sections A,G,H,I, and J</td>
</tr>
<tr>
<td></td>
<td>If Yes then tick this box and fill in sections A, B, C, D, E, F, G, H, I, and J.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>A. Age</th>
<th>Sex</th>
<th>Ethnicity</th>
<th>1st admission</th>
<th>Catatonic symptoms before?</th>
<th>DSM -5 Diagnosis in file?</th>
<th>Substance Use?</th>
<th>Another medical condition</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt; 16</td>
<td>6</td>
<td>36</td>
<td>&gt; 65</td>
<td>F (0)</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>6 - 35</td>
<td>M (1)</td>
<td>B</td>
<td>C</td>
<td>I</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>35 - 65</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>65</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>No of previous admissions</th>
<th>No of times had catatonia previously</th>
</tr>
</thead>
<tbody>
<tr>
<td>Not known</td>
<td>No</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Name of BZD given</th>
<th>Blood Pressure</th>
<th>Pulse</th>
<th>Body Temp</th>
<th>Respiratory Rate/ O2 Sats</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lorazepam</td>
<td>Pulse &lt;70</td>
<td>71-100</td>
<td>&lt;35</td>
<td>&lt;90%</td>
</tr>
<tr>
<td>Clonazepam</td>
<td>35-37</td>
<td>91-93</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>B. BFCR Scale Score</th>
<th>BZD Given</th>
<th>Name of BZD given</th>
<th>Blood Pressure</th>
<th>Pulse</th>
<th>Body Temp</th>
<th>Respiratory Rate/ O2 Sats</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes / No</td>
<td>Yes</td>
<td>Lorazepam</td>
<td>Pulse &lt;70</td>
<td>71-100</td>
<td>&lt;35</td>
<td>&lt;90%</td>
</tr>
<tr>
<td>If yes Doses given 1-2</td>
<td>Clonazepam</td>
<td>35-37</td>
<td>91-93</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Initial Score</td>
<td>1&lt;sup&gt;st&lt;/sup&gt; dose</td>
<td>2&lt;sup&gt;nd&lt;/sup&gt; dose</td>
<td>3&lt;sup&gt;rd&lt;/sup&gt; dose</td>
<td>4&lt;sup&gt;th&lt;/sup&gt; dose</td>
<td>5&lt;sup&gt;th&lt;/sup&gt; dose</td>
<td></td>
</tr>
<tr>
<td>--------------</td>
<td>------------------</td>
<td>------------------</td>
<td>------------------</td>
<td>------------------</td>
<td>------------------</td>
<td></td>
</tr>
<tr>
<td>&lt;6</td>
<td>&lt;6</td>
<td>&lt;6</td>
<td>&lt;6</td>
<td>&lt;6</td>
<td>&lt;6</td>
<td></td>
</tr>
<tr>
<td>6-12</td>
<td>6-12</td>
<td>6-12</td>
<td>6-12</td>
<td>6-12</td>
<td>6-12</td>
<td></td>
</tr>
<tr>
<td>24-36</td>
<td>24-36</td>
<td>24-36</td>
<td>24-36</td>
<td>24-36</td>
<td>24-36</td>
<td></td>
</tr>
<tr>
<td>&gt;36</td>
<td>&gt;36</td>
<td>&gt;36</td>
<td>&gt;36</td>
<td>&gt;36</td>
<td>&gt;36</td>
<td></td>
</tr>
</tbody>
</table>

**Systolic:**
- <120
- 120 - 139
- 140 - 180
- 181 - 220
- >220

**Diastolic:**
- <70
- 80 - 90
- 91 - 110
- 110 - 120
- >120
- 101 - 120
- 121 - 160
- >160
- 38 - 40
- >40

**Other Treatment:**
- Diazeptam
- Midazolam

3 - 45 or more
### C. Length of time and degree of response to BZD

<table>
<thead>
<tr>
<th>Time Period</th>
<th>Degree of Response</th>
</tr>
</thead>
<tbody>
<tr>
<td>1st hour after admission</td>
<td>Mild = Less than 25% reduction in No. of symptoms</td>
</tr>
<tr>
<td>2 to 6 hours after admission</td>
<td>Moderate = 25% to 50% reduction in No. of symptoms</td>
</tr>
<tr>
<td>7 to 47 hours after admission</td>
<td>Good = Response of more than 50% reduction in No. of symptoms</td>
</tr>
</tbody>
</table>

Reason ECT was not given after the 1st 3 days of admission (from clinical notes): Response to BZD not sustained.

### D. ECT and response

<table>
<thead>
<tr>
<th>Number of Sessions</th>
<th>Response</th>
<th>Maintenance ECT prescribed or required?</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt; 4</td>
<td>Nil</td>
<td>Yes, prescribed?</td>
</tr>
<tr>
<td>5-9</td>
<td>Remission of catatonia</td>
<td>If so what is the No. of sessions?</td>
</tr>
<tr>
<td>10-12</td>
<td>Other (specify)</td>
<td>No, not prescribed</td>
</tr>
<tr>
<td>≥ 12</td>
<td>Time to 50% improvement</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Time to full Resolution</td>
<td></td>
</tr>
<tr>
<td></td>
<td>&lt; 3 days</td>
<td></td>
</tr>
<tr>
<td></td>
<td>4-7 days</td>
<td></td>
</tr>
<tr>
<td></td>
<td>&gt; 1 week</td>
<td></td>
</tr>
</tbody>
</table>

### E. Duration of Catatonia prior to admission if known

<table>
<thead>
<tr>
<th>Duration</th>
<th>Mostly Excited Form?</th>
<th>Mostly Slowed Form?</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt; 3 days</td>
<td>NOT known</td>
<td>OR</td>
</tr>
<tr>
<td>4 days to 2 weeks</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3 to 4 weeks</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&gt; 4 weeks</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### F. Type of onset

<table>
<thead>
<tr>
<th>Hours to days</th>
<th>Mostly Excited Form?</th>
<th>Mostly Slowed Form?</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gradual</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fluctuating</td>
<td></td>
<td></td>
</tr>
<tr>
<td>G. Food Security</td>
<td></td>
<td></td>
</tr>
<tr>
<td>------------------</td>
<td>---</td>
<td>---</td>
</tr>
<tr>
<td>Often True</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sometimes True</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Never True</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Don’t know</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

1. Within the past 12 months, we worried whether our food would run out before we got money to buy more.

<table>
<thead>
<tr>
<th>H. Substances</th>
<th>YES</th>
<th>NO</th>
<th>Alcohol</th>
<th>Cannabis</th>
<th>Amphet</th>
<th>Heroin</th>
<th>Metamphet</th>
<th>Cocaine</th>
<th>Opiods</th>
<th>Nicotine</th>
<th>Other (Specify)</th>
</tr>
</thead>
</table>

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance Supplemental material which has been supplied by the author(s)
### I. Medical Illness

<table>
<thead>
<tr>
<th>Illness</th>
<th>No</th>
<th>Yes</th>
<th>If Yes, chose from the following if on history only</th>
<th>If Yes, choose from the following if current</th>
<th>If HIV</th>
</tr>
</thead>
<tbody>
<tr>
<td>HPT</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DM</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Epilepsy</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HIV</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Head Trauma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TB</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SLE or Auto/I</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other (specify)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### J. Investigations:

#### 1. CK – Creatinine Kinase
- CK (u/l):
  - CK ≤ 200
  - CK > 2000

#### 2. Fe – Iron
- Fe µmol/l:
  - Fe ≤ 9
  - Fe ≥ 30

#### 3. B12 – Vitamin B12
- B12 pmol/l:
  - B12 ≤ 107
  - B12 ≥ 221

#### 4. TSH – Thyroid Stimulating Hormone
- TSH miu/l:
  - TSH ≤ 0.38
  - TSH ≥ 5.33

#### 5. T4 – Thyroid Hormone
- T4 pmol/l:
  - T4 ≤ 7.2
  - T4 ≥ 16.4

#### 6. ANF – Nuclear Factor Rheumatoid Factor
- Normal T4:
  - Normal T4: 7.2 to 16.4

#### Endocrine
- Normal TSH:
  - Normal TSH: 0.38 to 5.33
- Cortisol (AM):
  - Cortisol (AM): 185 to 617
- Cortisol (PM):
  - Cortisol (PM): ≤ 276

**END OF INPATIENT DATA CAPTURING SECTIONS**
BEGINNING OF OUTPATIENT FOLLOW UP SECTION FOR PATIENTS WHO HAD CATATONIA

<table>
<thead>
<tr>
<th>K. Follow-up Period ONLY</th>
<th>Date of Discharge</th>
<th>1 month</th>
<th>2 months</th>
<th>3 months</th>
<th>Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>Please tick the applicable box</td>
<td>Recurrence of Catatonia?</td>
<td>Recurrence of Catatonia?</td>
<td>Recurrence of Catatonia?</td>
<td>Other?</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td></td>
</tr>
<tr>
<td></td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Re-Admission?</td>
<td>Re-Admission?</td>
<td>Yes</td>
<td>Yes</td>
<td>Other?</td>
</tr>
<tr>
<td></td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td></td>
</tr>
<tr>
<td></td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>Please describe (in your own words) your experience/ of the catatonic episode in terms of your thoughts, feelings and behaviour</td>
<td>Eyacelwa uchaze (ngawakho amazwi)</td>
<td>Eyacelwa uchaze (ngawakho amazwi)</td>
<td>Eyacelwa uchaze (ngawakho amazwi)</td>
<td>Participant response recorded verbatim (use audio recorder)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Thoughts</td>
<td>Thoughts</td>
<td>Thoughts</td>
<td>Thoughts</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Feelings</td>
<td>Feelings</td>
<td>Feelings</td>
<td>Feelings</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Behaviour</td>
<td>Behaviour</td>
<td>Behaviour</td>
<td>Behaviour</td>
<td></td>
</tr>
</tbody>
</table>
### APPENDIX 2: CATATONIA RATING SCALE

#### BUSH-FRANCIS CATATONIA RATING SCALE

**Use presence or absence of items 1-14 for screening**  
**Use the 0-3 scale for items 1-23 to rate severity**

<table>
<thead>
<tr>
<th>Item</th>
<th>Description</th>
<th>Rating</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td>Excitement:</td>
<td>0 = Absent</td>
</tr>
<tr>
<td></td>
<td>Extremes hyperactivity, constant motor unrest which is apparently non-purposive. Not to be attributed to anxiety or goal-directed activity</td>
<td></td>
</tr>
<tr>
<td>2.</td>
<td>Immobility/Inflexible</td>
<td>0 = Absent</td>
</tr>
<tr>
<td></td>
<td>Extremes hypoactivity, immobility, minimally responsive to stimuli</td>
<td></td>
</tr>
<tr>
<td>3.</td>
<td>Mutism:</td>
<td>0 = Absent</td>
</tr>
<tr>
<td></td>
<td>Virtually unresponsive or minimally responsive</td>
<td></td>
</tr>
<tr>
<td></td>
<td>1 = Virtually unresponsive to majority of questions, incomprehensible whisper</td>
<td></td>
</tr>
<tr>
<td></td>
<td>2 = Speaks less than 20 words/5 min</td>
<td></td>
</tr>
<tr>
<td></td>
<td>3 = No speech</td>
<td></td>
</tr>
<tr>
<td>4.</td>
<td>Staring:</td>
<td>0 = Absent</td>
</tr>
<tr>
<td></td>
<td>Fixed gaze, little or no visual scanning of environment, decreased blinking</td>
<td></td>
</tr>
<tr>
<td></td>
<td>1 = Poor eye contact, repeatedly gazes, less than 20 seconds between shifting of attention, decreased blinking</td>
<td></td>
</tr>
<tr>
<td></td>
<td>2 = Gaze held longer than 20 seconds, occasionally shifts attention</td>
<td></td>
</tr>
<tr>
<td></td>
<td>3 = Fixed gaze, non-responsive</td>
<td></td>
</tr>
<tr>
<td>5.</td>
<td>Posturing/Posture:</td>
<td>0 = Absent</td>
</tr>
<tr>
<td></td>
<td>Spontaneous maintenance of posture(s), including muntane (e.g. setting or standing for long periods without reading)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>1 = Less than 1 minute</td>
<td></td>
</tr>
<tr>
<td></td>
<td>2 = Greater than one minute, less than 15 minutes</td>
<td></td>
</tr>
<tr>
<td></td>
<td>3 = Rises from posture, or muntane maintained more than 15 minutes</td>
<td></td>
</tr>
<tr>
<td>6.</td>
<td>Gimmancing:</td>
<td>0 = Absent</td>
</tr>
<tr>
<td></td>
<td>Maintenance of odd facial expressions.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>1 = Less than 10 seconds</td>
<td></td>
</tr>
<tr>
<td></td>
<td>2 = Less than 1 minute</td>
<td></td>
</tr>
<tr>
<td></td>
<td>3 = Rises or maintained more than 1 minute</td>
<td></td>
</tr>
<tr>
<td>7.</td>
<td>Echopraxia/Echolalia:</td>
<td>0 = Absent</td>
</tr>
<tr>
<td></td>
<td>Mimicking of examiner's movements/speech</td>
<td></td>
</tr>
<tr>
<td></td>
<td>1 = Occasional</td>
<td></td>
</tr>
<tr>
<td></td>
<td>2 = Frequent</td>
<td></td>
</tr>
<tr>
<td></td>
<td>3 = Constant</td>
<td></td>
</tr>
<tr>
<td>8.</td>
<td>Stereotypy:</td>
<td>0 = Absent</td>
</tr>
<tr>
<td></td>
<td>Repetitive, non-goal-directed motor activity (e.g. finger-play, repeatedly touching, scratching or rubbing self), abnormality inherent in act but not in frequency</td>
<td></td>
</tr>
<tr>
<td></td>
<td>1 = Occasional</td>
<td></td>
</tr>
<tr>
<td></td>
<td>2 = Frequent</td>
<td></td>
</tr>
<tr>
<td></td>
<td>3 = Constant</td>
<td></td>
</tr>
<tr>
<td>9.</td>
<td>Manicisms:</td>
<td>0 = Absent</td>
</tr>
<tr>
<td></td>
<td>Odd, purposeful movements (hopping or walkingCOPE, skulking about or exaggerated imitation of mundane movements), abnormality inherent in act but not in frequency</td>
<td></td>
</tr>
<tr>
<td></td>
<td>1 = Occasional</td>
<td></td>
</tr>
<tr>
<td></td>
<td>2 = Frequent</td>
<td></td>
</tr>
<tr>
<td></td>
<td>3 = Constant</td>
<td></td>
</tr>
<tr>
<td>10.</td>
<td>Verfilleration:</td>
<td>0 = Absent</td>
</tr>
<tr>
<td></td>
<td>Repetition of phrases or sentences (like a scratched record)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>1 = Occasional</td>
<td></td>
</tr>
<tr>
<td></td>
<td>2 = Frequent</td>
<td></td>
</tr>
<tr>
<td></td>
<td>3 = Constant</td>
<td></td>
</tr>
<tr>
<td>11.</td>
<td>Rigidity:</td>
<td>0 = Absent</td>
</tr>
<tr>
<td></td>
<td>Maintenance of a rigid position despite efforts to be moved, exclude if cog-wheeling or tracitor present</td>
<td></td>
</tr>
<tr>
<td></td>
<td>1 = Mild resistance</td>
<td></td>
</tr>
<tr>
<td></td>
<td>2 = Moderate</td>
<td></td>
</tr>
<tr>
<td></td>
<td>3 = Severe, cannot be repositioned</td>
<td></td>
</tr>
<tr>
<td>12.</td>
<td>Negativism:</td>
<td>0 = Absent</td>
</tr>
<tr>
<td></td>
<td>Apparently resistant to instructions or attempts to move/examine patient. Contrary behavior, does exact opposite of instruction</td>
<td></td>
</tr>
<tr>
<td></td>
<td>1 = Mild resistance</td>
<td></td>
</tr>
<tr>
<td></td>
<td>2 = Moderate resistance and/or exceptionally contrary</td>
<td></td>
</tr>
<tr>
<td></td>
<td>3 = Severe resistance and/or continually contrary</td>
<td></td>
</tr>
<tr>
<td>13.</td>
<td>Waxy Flexibility:</td>
<td>0 = Absent</td>
</tr>
<tr>
<td></td>
<td>During repositioning of patient, patient offers initial resistance before allowing himself to be repositioned, similar to that of a heating candle</td>
<td></td>
</tr>
<tr>
<td></td>
<td>1 = Minimal PO intake/interaction for less than 1 day</td>
<td></td>
</tr>
<tr>
<td></td>
<td>2 = Minimal PO intake/interaction for more than 1 day</td>
<td></td>
</tr>
<tr>
<td></td>
<td>3 = No PO intake/interaction for 3 days or more</td>
<td></td>
</tr>
</tbody>
</table>
### BUSH-FRANCIS CATATONIA RATING SCALE (CONT.)

<table>
<thead>
<tr>
<th>Item</th>
<th>Description</th>
<th>Scoring</th>
</tr>
</thead>
<tbody>
<tr>
<td>15. Inopinability</td>
<td>Patient suddenly engages in inappropriate behavior (e.g., runs down hallway, starts screaming or takes off clothes) without provocation. Alternatively can give no, or only a false explanation.</td>
<td>0 = Absent, 1 = Occasional, 2 = Frequent, 3 = Constant or not identifiable</td>
</tr>
<tr>
<td>16. Automatic obedience</td>
<td>Exaggerated cooperation with examiner's request or spontaneous continuation of movement requested.</td>
<td>0 = Absent, 1 = Occasional, 2 = Frequent, 3 = Constant</td>
</tr>
<tr>
<td>17. Mental state</td>
<td>&quot;Angerosepp lapa&quot; arm raising in response to light pressure of finger, despite instruction to the contrary.</td>
<td>0 = Absent, 3 = Present</td>
</tr>
<tr>
<td>18. Amnesticity</td>
<td>Patient appears momentarily &quot;stuck&quot; in indecisive, hesitant movement</td>
<td>0 = Absent, 3 = Present</td>
</tr>
<tr>
<td>19. Perserveration</td>
<td>Persistent/returns to same topic or persists with movement.</td>
<td>0 = Absent, 3 = Present</td>
</tr>
<tr>
<td>20. Autonomic abnormality</td>
<td>Circum temperature, BP, pulse, respiratory rate, diaphoresis.</td>
<td>0 = Absent, 1 = Abnormality of one parameter (excluding pre-existing hypertension), 2 = Abnormality of two parameters, 3 = Abnormality of three or more parameters</td>
</tr>
<tr>
<td>21. Gegenhalten</td>
<td>Resistance to passive movement which is proportional to strength of the stimulus, appears automatic rather than willful</td>
<td>0 = Absent, 3 = Present</td>
</tr>
<tr>
<td>22. Grasp reflex</td>
<td>Per neurosensory exam.</td>
<td>0 = Absent, 3 = Present</td>
</tr>
<tr>
<td>23. Combative ness</td>
<td>Usually in an undirected manner, with no, or only a facile explanation afterwards.</td>
<td>0 = Absent, 1 = Occasionally strikes out, low potential for injury, 2 = Frequently strikes out, moderate potential for injury, 3 = Serious danger to self</td>
</tr>
</tbody>
</table>

**TOTAL:**_________
APPENDIX 3: INFORMED CONSENT FORM INFORMED CONSENT – ENGLISH

INFORMED CONSENT FOR A STUDY ON CATATONIA

Dear Participant or Relative

We are requesting your consent to enroll you in a study on catatonia and how the symptoms respond to the treatment you are going to be given.

----------------------------------------

YES, I AGREE TO BE ENROLLED

I ………………………………………………………………………………………………......
agree in voluntarily taking part in the study as explained to me by the doctor/nurse

OR

(In cases where the patient is incapable of giving consent but is not opposed to taking part in the study, then a relative or custodian may provide informed consent by also signing below)

I …………………………………… being the ......................................................... of ………………………………………
……….. willingly agree that he/she may take part in the study which has been explained to us by the doctor/nurse

Signature of participant/relative/ custodian:

Signed by …………………………………… at.................................................................on the
………… of........................................... 2019

----------------------------------------
NO, I DO NOT AGREE TO BE ENROLLED

I

………………………………………………………………………………………………......
do not agree in taking part in the study as explained to me by the doctor/ nurse OR

I .......................................................... being the ......................................................... of
……………………………………… do not agree that he/she may take part in the study which has been
explained to us by the doctor/ nurse

Signature of participant/relative/ custodian:

……………………………………………………………………

FOR OFFICE USE ONLY: ASSESSMENT OF CAPACITY TO CONSENT BASED ON UBACC

<table>
<thead>
<tr>
<th>Does the patient….</th>
<th>Yes</th>
<th>No</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Understand the information relevant to the decision?</td>
<td>........</td>
<td>........</td>
</tr>
<tr>
<td>2. Retain the information long enough to consider it?</td>
<td>........</td>
<td>........</td>
</tr>
<tr>
<td>3. Weigh the information as part of the decision-making process?</td>
<td>........</td>
<td>........</td>
</tr>
<tr>
<td>4. Communicate their decision in some way?</td>
<td>........</td>
<td>........</td>
</tr>
</tbody>
</table>

Please Note: Should there be a no answer to any of the 4 questions above then the patient lacks capacity to consent and a relative or custodian may then be requested to provide informed consent.
INFORMED CONSENT - ISIXHOSA

IPHEPHA-MVUME LOPHANDO NGESIGULO SE-CATATONIA

Mthathi-nxaxheba obekekileyo okanye Mzali okanye sizalwane esibekekileyo

Sicela imvume yakho yokuphanda nzulu ngeempawu zesi sigulo i-catatonia, nokuba unyango ozakulufumana luzakusebenezela njani na.
Ndiye ndanikwa iphepha elichaza ngolu phando kwaye ndiluchazelwe ngu

EWE NDIYAVUMA

Mna (faka igama lakho apha) ..........................................................
ndiyazikhethela ukulungenela olu phando ndiluchazelwe ngugqirha okanye umongikazi, kwaye andinyanzeliswa.

OKANYE

Ukuba umntu akakwazi ukunika imvume ngasizathu sithile, kodwa abe engali ukulungenela uphando, kungatyikitya umzali okanye isizalwane
Isayinwe ngu………………………. e……………………….. ngomhla we…………..
kwinyanga ye……………….ku 2019

HAYI NDIKHETHA UKUNGALUNGENELI OLU PHANDO
Mna (faka igama lakho apha) ................................. ndikhetha ukuba ndingalunengi olu phando ndiluchazelwe ngugqirha okanye umongikazi
Mna ndingu…………………………………………..(Chaza uhlobene njani nomthathi-nxaxheba)
ka………………………………(igama lomthathi nxaxheba)
APPENDIX 4: INFORMATION LEAFLETS IN ENGLISH AND XHOSA

4.1 - INFORMATION LEAFLET (XHOSA)

Iphepha lokwazisa umthathi-nxaxheba kuphando lwegisigulo i-Catatonia

Mthathi-nxaxheba obekekileyo **okanye** Mzali okanye szalwane esibekekileyo

Ngale nwadi sikwazisa malunga ngophando nzulu oluqhutywa ziinzululwazi ezifuna ukufunda nzulu ngesigulo ekuthiwa yi-catatonia kweli ziko lempilo. Unyango obuhleli uzakulufumuna alusayi kutshintsha okanye luphazamiseke wakuthatha inxaxheba kolu phando.

**Yintoni i-catatonia?**

I-catatonia sisigulo esiye sibangele ukuphazamiseka kwindlela umuntu ashukuma ngayo apha emzimbeni. Kwabanye abantu sibangela ukuba umzimba lo ucothe kakhulu okanye angakwazi kushuma, umuntu azive eqinile, athi nokuba uyafuna ukushumisa umzimba wakhe njengesiqhelo angakwazi. Ide ibangele loo nto ngelinye ixesha ukuba umuntu aphethe ehleli ndawoninye okanye emile ndawoninye de kugqithe imizuzu eminizzi okanye iyiyere zibe liqela. Iyakwazi nokubangela ukuba umuntu angakwazi ukuphuma kwasebhedini, angakwazi kuzityisa, angakwazi kuzihlamba, asoloko elele ebhedini okanye ehleli esitulweni.

Kwelinye icala i-catatonia iyakwazi ukuphinda intshukumo ekuphetha zama phethe emnye umuntu abetha-bethe amanqindi emoyeni, omnye athi nokuba usebhedini kube ngathi unyomfa ibhaysikili into engapheliyo. Babakhona nabaphetha bethetha into enye,
Isaynwe e…………………………… ngomhla we………….. kwinyanga ye ................................ ku 2019
Utyikitya apha wena okanye umzali okanye isizalwane

APPENDIX 4: INFORMATION LEAFLETS IN ENGLISH AND XHOSA

4.1 - INFORMATION LEAFLET (XHOSA)

Iphepha lokwazisa umthathi-nxaxheba kuphando lwesigulo i-Catatonia
Mthathi-nxaxheba obekekileyo okanye Mzali okanye sizalwane esibekekileyo
Ngale ncwadi sikwazisa malunga ngophando nzulu oluqhutywa ziinzululwazi ezifuna ukufunda nzulu ngesigulo ekuthiwa yi-catatonia kweli ziko lempilo. Unyango obuhleli uzakulufumna alusayi kutshintsha okanye lumphazamiseke wakuthatha inxaxheba kolo phando.

Yintoni i-catatonia?
I-catatonia sisigulo esiye sibangele ukuphazamiseka kwindlela umntu ashukuma ngayo apha emzimbeni. Kwabanye abantu sibangela ukuba umzimba lo ucothe kakhulu okanye ungakwazi kushuma, umntu azive eqinile, athi nokuba uyaafuna ukushumisa umzimba wakhe njengesiqhelo angakwazi. Ide ibangele loo nto ngelinye ixesha ukuba umntu aphethe ehleli ndawoninye okanye emile ndawoninye de kugqithe imizuzu emininzi okanye iyiyile zibe liqela. Iyakwazi nokubangela ukuba umntu angakwazi ukuphuma kwasebhedini, angakwazi kuzityisa, angakwazi kuzihlamba, asoloko elele ebhedini okanye ehleli esitulweni.
Kwelinye icala i-catatonia iyakwazi ukubangela ukuba umntu athi ngoku sele eqalile ukushukuma esithi wenza into ethile, suka umzimba lo uqine, aphethe amalungu omzimba afana neengalo, izandla, imilenze okanye inyawo zilenga emoyeni angakwazi ukuphinda iziyakwazi kune eqalile ukuvela. Intambo nentloko nazo ziyakwazi ukuphinda zika ngoku komzimba kuvela ngokhulume. Okokugqibela, i-catatonia iyakwazi ukuphinda ibangele intshukumo engaphaya kunesiqhelo, aphethe umntu eshuku-shukuma kakhulu, angahlali ndawoninye okanye angazinzi. Abanye baye bazule ndawoninye, abanye baqhwabe izandla unomphelo okanye banqwale kungenjalo baninike intloko into engapheliyo. Iyakwazi nokuvela ngokuba omnye umntu abetha-bethe amanqindi emoyeni, omnye athi nokuba usebhedini kube ngathi unyomfa ibhaysikili into engapheliyo. Babakhona nabaphetha bethetha into enye,
okanye benze isikhalo esiphindaphindwayo okanye nayiphina intsholo abanye bayiqhube imizuzu emininzi okanye iiyure zide zibe liqela. Bakhona ke nabanye abanye balinganise loo nto ithethwa ngumntu ophambi kwabo kungenjalo balinganisa loo nto bayibona isenziwa ngumntu ophambi kwabo.

**Ibangelwa yintoni i-catatonia?**


**Luqulethe ntoni olu phando?**


Zimbini izinto esifuna ukuziqwalasela kolu phando nge-catatonia:

1. Ingaba bangaphi abantu abafunyanwa sesi sigulo kule ngingqi?
2. Ingaba zikhona izinto ezingunobangela wokuba abanye abantu bafunyanwe sesi sigulo abanye basinde, mhlawumbi njenkobubudala bomntu, isini okanye ezinye izigulo zomzimba?

Ukuba ndifunyaniswe ndinazo imipawu ze-catatonia loo nto ithetha ukuthi?
Ukuba ufunyaniswe unazo ezine ezeli mpawu ze-catatonia, uqgira wakho wokunika unyangako lapho
lwesiqhelo okanye enze uvuvelo ebhleli ezakulwenza kakade olunxulumene nempilo yakho.

Kuza kwenziwa ntoni ngeziphumo zolu phando?
Iziphumo zolu phando zizakudityaniswa zibhalwe kufndiswe abanye oogqirha neenzululwazi malungu nesigulo, kwinkomfa zoogqirha neenzululwazi.

Ndithini ukuba ndinemibuzo?
Ukuba unemibuzo ngolu phando, cela ukuthetha nogqirha wakho okanye umangikazi ozakube encedisa
kololo phando.

Siyabulela!
Sibilela kakhulu ngexesha lakho nokuzixhesha kwakho ngolu phando.

4.2 - INFORMATION LEAFLET (ENGLISH)

Information Leaflet about a Study of Catatonia

Dear Participant / Parent/ Relative

This leaflet is provided to inform you about a study being conducted by researchers who would like to
investigate a condition called catatonia at his health facility. The usual care you were going to get will not
be changed or disturbed through taking part in this study.

What is catatonia?
Catatonia is a condition that affects the way a person moves his whole body or body parts. In some people
it slows down the body considerably to the point where some will stop moving completely, causing the
person to feel very stiff such that they are unable to move even when they want to. This may lead to a
person remaining in one position for a very long time (whether sitting or standing) to the point of many minutes or even hours. It can even cause some people to be bedridden, unable to feed themselves, or wash or attend to other daily needs.

Catatonia can also cause a person to appear frozen even after initiating a particular action, resulting in body parts like legs, arms, hands, or feet being frozen in awkward or unusual looking positions. The head and or neck may also be tilted at awkward angles. The change in movement can often occur suddenly.

Lastly catatonia can also cause an abnormality of excessive movement which is more than normal. A person may show excessive movement that lasts up to many minutes or hours with a seeming inability to stay still. Some people may pace up and down, others may clap or wave for long periods lasting minutes to hours, while others may show head nodding, head shaking, grimacing, etc. Some people have been seen to do shadow boxing or cycling movements even when lying down. It may also appear as repetitive speech of the same phrase, a cry or shout or other odd sound that can last for hours. Others may repeat what they hear around them non-stop or they may mimic actions of those around them as well.

**What causes catatonia?**

Catatonia may be seen with a number of mental illnesses but it can also be associated with some other medical conditions. The problem we run into as doctors is when a person presents with the first time with this syndrome it may be difficult in the beginning to know what the underlying cause is i.e. whether the cause is a mental condition or another medical condition. This is why conducting research on catatonia is so important.

**What does this research involve?**

We are looking at ensuring that everybody who is admitted into this unit is examined and screened for symptoms and signs of catatonia. Your admitting doctor will examine you as usual, which will include an initial screen for catatonia through examination only. Following this, a trained research assistant who is a nurse will proceed to do a full screen using a rating scale, to ensure that no other signs of catatonia were missed. If the research assistant finds any additional signs of catatonia, they will tell your treating doctor. In addition, the nurse may ask you questions like when did the symptoms start and how fast did they appear etc. She or he will note down your answers but will not include details like your name or your address which
can identify who you are. This further screening by the nurse not expected to take longer than 5 to 10 minutes. The information to be collected for the study about your condition is about the signs and symptoms and the few questions already mentioned to do with the illness, nothing more. There are two questions we would like to investigate about catatonia:

1. How many people experience this condition in this area?

2. Are there particular characteristics that make some people more prone to it and others less vulnerable to it like age, gender or other medical conditions?

Whatever we can learn about this condition, over and above what we know already will help us to come up with improved ways to diagnose it and to treat it in future. Taking part in this research will therefore help many people in future who may also get this illness.

There are no other tests you will be expected to take part in for this study. Whatever other tests or treatment interventions that follow will be those that your doctor would have undertaken anyway to help you manage your condition and get you better.

**If I am found to show some of the symptoms or signs of catatonia what does that mean?**

If you are found to have some signs and symptoms of catatonia, the research nurse will inform your treating doctor, so that your doctor can give you the appropriate and usual treatment for your condition. Your doctor may also decide to do more tests which would be what they would have done anyway even if you were not part of the study, in order to manage your condition.

**What will be done with the results of the study?**

The results of the study will be collected and put together to present to scientific congresses so that other doctors and scientists can learn from them.

**What should I do if I have more questions?**

If you have more questions, ask your treating doctor or the researcher, research assistant or nurse.

**Thank you! Thank you very much for your patience and for spending the few minutes on this study.**
APPENDIX 5: INSTITUTIONAL PERMISSIONS – DORA NGINZA HOSPITAL

Provincial of
EASTERN CAPE
HEALTH

DORA NGINZA REGIONAL HOSPITAL

To
Mr P Tsibhotene
Chief Executive Officer
Dora Nginza Hospital

From
Dr A Bronkhorst, Prof S van Wyk and Prof Z Zingela
Department of Psychiatry

Subject
DEPARTMENT OF PSYCHIATRY REQUEST FOR CEO APPROVAL OF DEPARTMENTAL RESEARCH

Date
08 November 2018

Introduction
The Department of Psychiatry and Walter Sisulu University have identified research projects in catatonia as a priority for the Eastern Cape due to the severity of the illness and the potentially negative outcomes resulting from delay in recognition of the condition.

Requested support
CEO approval and support for the research project on Catatonia: “Catatonia as a manifestation of serious mental illness: prevalence, presentation, management and outcomes in a mental health unit”, is hereby requested on behalf of the investigators to initiate this study in the Department of Psychiatry in Dora Nginza Hospital.

Conclusion
This project is also expected to yield support for other ongoing and planned registrar research projects on Catatonia. Thank you for considering this request.

A Bronkhorst
S van Wyk
Z Zingela

The request for approval is hereby granted / not granted (please delete as appropriate)

Signature: ..................................  Designation: CEO ........ Date: 08.11.2018

Name: ...............................
APPENDIX 6: INSTITUTIONAL PERMISSIONS

APPROVAL FROM EC HEALTH RESEARCH COMMITTEE

APPENDIX VI

Eastern Cape Department of Health

Enquiries: Malatia Zichewe  
Tel No: 041 699 0710  
Fax No: 0416421459

Date: 10 December 2017

Dear Professor Zingela

Re: Catatonia As A Presentation For Severe Mental Illness: Prevalence Of Catatonia In Two Mental Health Units In Urban And Rural South Africa (EC_201712_015)

The Department of Health would like to inform you that your application for conducting a research on the abovementioned topic has been approved based on the following conditions:

1. During your study, you will follow the submitted protocol with ethical approval and can only deviate from it after having written approval from the Department of Health in writing.
2. You are advised to ensure, observe and respect the rights and culture of your research participants and maintain confidentiality of their identities and shall remove or not collect any information which can be used to link the participants.
3. The Department of Health expects you to provide a progress on your study every 3 months (from date you received this letter) in writing.
4. At the end of your study, you will be expected to send a full written report with your findings and implementable recommendations to the Epidemiological Research & Surveillance Management. You may be invited to the department to come and present your research findings with your implementable recommendations.
5. Your results on the Eastern Cape will not be presented anywhere unless you have shared them with the Department of Health as indicated above.

Your compliance in this regard will be highly appreciated.

[Signature]

SECRETARIAT: EASTERN CAPE HEALTH RESEARCH COMMITTEE
APPENDIX 7: ETHICS APPROVAL

NELSON MANDELA UNIVERSITY
PO Box 77003, Nelson Mandela University, Port Elizabeth, 6031, South Africa 
manela.ac.za

Chairperson: Research Ethics Committee (Human)
Tel: +27 (0)41 304 3749
shadene.govender@mandela.ac.za
NHREC registration nr: REC-042606-025

Ref: [H20-HEA-PSY-002] / Approval
18 August 2020
Prof L Stroud
Faculty: Health Sciences
Dear Prof Stroud

CATATONIA AS A MANIFESTATION OF SERIOUS MENTAL ILLNESS: PREVALENCE, PRESENTATION, MANAGEMENT AND OUTCOMES OF CATATONIA IN A MENTAL HEALTH UNIT

PRP: Prof L Stroud
PI: Dr Z Zingela

Your above-entitled application served at the Research Ethics Committee (Human) (meeting of 29 July 2020) for approval. The study is classified as a high risk study. The ethics clearance reference number is H20-HEA-PSY-002 and approval is subject to the following conditions:

1. The immediate completion and return of the attached acknowledgement to Imtiaz.khan@mandela.ac.za, the date of receipt of such returned acknowledgement determining the final date of approval for the study where after data collection may commence.
2. Approval for data collection is for 1 calendar year from date of receipt of above mentioned acknowledgement.
3. The submission of an annual progress report by the PRP on the data collection activities of the study (form RECH-004 available on Research Ethics Committee (Human) portal) by 15 November this year for studies approved/extended in the period October of the previous year up to and including September of this year, or 15 November next year for studies approved/extended after September this year.
4. In the event of a requirement to extend the period of data collection (i.e. for a period in excess of 1 calendar year from date of approval), completion of an extension request is required (form RECH-005 available on Research Ethics Committee (Human) portal).
5. In the event of any changes made to the study (excluding extension of the study), completion of an amendments form is required (form RECH-006 available on Research Ethics Committee (Human) portal).
6. Immediate submission (and possible discontinuation of the study in the case of serious events) of the relevant report to RECH (form RECH-007 available on Research Ethics Committee (Human) portal) in the event of any unanticipated problems, serious incidents or adverse events observed during the course of the study.
7. Immediate submission of a Study Termination Report to RECH (form RECH-008 available on Research Ethics Committee (Human) portal) upon expected or unexpected closure/termination of study.
8. Immediate submission of a Study Exception Report of RECH (form RECH-009 available on Research Ethics Committee (Human) portal) in the event of any study deviations, violations and/or exceptions.
9. Acknowledgement that the study could be subjected to passive and/or active monitoring without prior notice at the discretion of Research Ethics Committee (Human).
Please quote the ethics clearance reference number in all correspondence and enquiries related to the study. For speedy processing of email queries (to be directed to jnlkhan@mandela.ac.za), it is recommended that the ethics clearance reference number together with an indication of the query appear in the subject line of the email.

We wish you well with the study.

Yours sincerely

[Signature]

Dr S Govender
Chairperson: Research Ethics Committee (Human)

Cc: Department of Research Development
    Faculty Manager: Health Sciences

Appendix 1: Acknowledgement of conditions for ethical approval
 FACULTY OF HEALTH SCIENCES
POSTGRADUATE EDUCATION, TRAINING, RESEARCH AND ETHICS UNIT

HUMAN RESEARCH COMMITTEE
CLEARANCE CERTIFICATE

PROTOCOL NUMBER : 067/2017

PROJECT : PREVALENCE OF CATATONIA IN TWO MENTAL HEALTH UNITS IN URBAN AND RURAL SOUTH AFRICA

INVESTIGATOR(S) : PROF Z ZINGELA

DEPARTMENT : PSYCHIATRY & BEHAVIOURAL SCIENCES

DECISION OF THE COMMITTEE : APPROVED

DATE OF APPROVAL : 07 MAY 2020

DURATION : 1 YEAR (07 MAY 2020 – 07 MAY 2021)

CONDITIONS : NONE

N.B You are required to provide the committee with a progress or outcome report of the research after every 6 months. The committee expects a report on any changes in the protocol as well as any untoward events that may occur at any time during the study not later than 7 days of knowing as the investigator/s.

WALTER SISULU UNIVERSITY
ACADEMIC HEALTH SERVICE COMPLEX OF THE EASTERN CAPE
POSTGRADUATE EDUCATION AND TRAINING FACULTY OF HEALTH SCIENCES
WALTER SISULU UNIVERSITY
P/IR AQ X 1, WSU, 6117, E.C
TEL: (047) 502 2100 / FAX: (047) 502 2101

DR EI NDEBIA
CHAIRPERSON

07.05.2020

DECLARATION OF INVESTIGATOR(S)
(To be completed in duplicate and one copy returned to the Research Officer at Office A8 02 GF 03 Administration Building, Sisson Street Campus, Fortaleza, Mthatha, WSU)

I/We fully understand the conditions under which I/any/we are authorized to carry out the abovementioned research and I/we guarantee to ensure compliance with these conditions. Should any departure to be contemplated from the research procedure as approved I/we undertake to submit the protocol to the Research Ethics Committee. I/We agree to a completion of a 6-monthly yearly progress report. The committee reserves the right to withdraw approval in the event that there are serious ethical violations.

______________________________ (Signature)
______________________________ (Date)

N. B. Please quote the protocol number in all enquiries.